Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort
Open Access
- 1 November 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (11), 3150-3160
- https://doi.org/10.1158/1055-9965.epi-08-0435
Abstract
Background: Results from the Women's Health Initiative trial raise new questions regarding the effects of estrogen therapy (ET) and estrogen plus progestin therapy (EPT) on breast cancer risk. Methods: We analyzed data from 126,638 females, ages 50 to 71 years at baseline, who completed two questionnaires (1995-1996 and 1996-1997) as part of the NIH-AARP Diet and Health Cohort Study and in whom 3,657 incident breast cancers were identified through June 30, 2002. Hormone-associated relative risks (RR) and 95% confidence intervals (CI) of breast cancer were estimated via multivariable regression models. Results: Among thin women (body mass index 2), ET use was associated with a significant 60% excess risk after 10 years of use. EPT was associated with a significantly increased risk among women with intact uteri, with the highest risk among current, long-term (≥10 years) users (RR, 2.44; 95% CI, 2.13-2.79). These risks were slightly higher when progestins were prescribed continuously than sequentially (<15 days/mo; respective RRs of 2.76 versus 2.01). EPT associations were strongest in thin women, but elevated risks persisted among heavy women. EPT use was strongly related to estrogen receptor (ER)-positive tumors, requiring consideration of this variable when assessing relationships according to other clinical features. For instance, ER- ductal tumors were unaffected by EPT use, but all histologic subgroups of ER+ tumors were increased, especially low-grade and mixed ductal-lobular tumors. Conclusions: Both ET and EPT were associated with breast cancer risks with the magnitude of increase varying according to body mass and clinical characteristics of the tumors. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3150–60)Keywords
This publication has 55 references indexed in Scilit:
- Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational StudyAmerican Journal of Epidemiology, 2008
- Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor–Defined Invasive Breast CancerJournal of Clinical Oncology, 2008
- Established breast cancer risk factors by clinically important tumour characteristicsBritish Journal of Cancer, 2006
- Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinomaCancer, 2004
- Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer studyInternational Journal of Cancer, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in EuropeInternational Journal of Cancer, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Design and Serendipity in Establishing a Large Cohort with Wide Dietary Intake DistributionsAmerican Journal of Epidemiology, 2001